Isthmus Partners’s Ingevity NGVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.65M Sell
65,240
-7,005
-10% -$479K 0.49% 51
2025
Q4
$4.28M Buy
72,245
+375
+0.5% +$20.4K 0.47% 55
2025
Q3
$3.97M Buy
71,870
+2,712
+4% +$141K 0.88% 30
2025
Q2
$2.98M Buy
69,158
+996
+1% +$38.4K 0.35% 77
2025
Q1
$2.7M Sell
68,162
-9,322
-12% -$413K 0.34% 75
2024
Q4
$3.16M Buy
77,484
+2,653
+4% +$110K 0.38% 69
2024
Q3
$2.92M Sell
74,831
-5,161
-6% -$206K 0.35% 78
2024
Q2
$3.5M Buy
+79,992
New +$3.87M 0.41% 73

Other funds holding NGVT

Isthmus Partners's NGVT Position: Q1 2026 in Review

Isthmus Partners reduced its Ingevity (NGVT) stake by 9.7% in Q1 2026, selling an estimated $479K and leaving 65,240 shares worth $4.65M. The position accounts for 0.49% of the portfolio, ranked #51.

Isthmus Partners first reported a position in NGVT in Q2 2024 and has held it in 8 quarters since. 307 funds tracked by Wall St. Rank hold NGVT as of Q1 2026.

  • Isthmus Partners held 65,240 shares of Ingevity worth $4.65M as of Q1 2026.
  • Isthmus Partners sold 7,005 Ingevity shares in Q1 2026, an estimated $479K.
  • Ingevity made up 0.49% of Isthmus Partners's portfolio in Q1 2026, its #51 holding.
  • Isthmus Partners first reported a position in Ingevity in Q2 2024 and has held it in 8 quarters since.
  • 307 funds tracked by Wall St. Rank held Ingevity as of Q1 2026.

Based on Isthmus Partners's 13F filing for Q1 2026, filed 30 Apr 2026.